Format

Send to

Choose Destination
Cancer Res. 2009 Jan 15;69(2):393-5. doi: 10.1158/0008-5472.CAN-08-2749.

MicroRNA silencing in primates: towards development of novel therapeutics.

Author information

1
Santaris Pharma, Kogle Allé 6, Hørsholm, Denmark and Wilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark.

Abstract

MicroRNAs (miRNA) comprise an abundant class of small noncoding RNAs that act as important posttranscriptional regulators of gene expression. Accumulating evidence showing that aberrantly expressed miRNAs play important roles in human cancers underscores them as potential targets for therapeutic intervention. Recent reports on efficient miRNA silencing in rodents and nonhuman primates using high-affinity targeting by chemically modified antisense oligonucleotides highlight the utility of such compounds in the development of miRNA-based cancer therapeutics.

PMID:
19147547
DOI:
10.1158/0008-5472.CAN-08-2749
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center